QLS31905 + gemcitabine + cisplatin

QLS31905 + gemcitabine + cisplatin is a combination therapy currently in clinical development for advanced solid tumors, notably Claudin18.2-positive cancers. **QLS31905** is a bispecific T cell engager (BiTE), engaging both Claudin18.2 (a tumor-associated antigen highly expressed in several gastrointestinal malignancies) and the CD3 receptor on T cells, thereby facilitating targeted T cell-mediated killing of tumor cells. **Gemcitabine** is a nucleoside analog antineoplastic agent that inhibits DNA synthesis via incorporation into DNA and inhibition of DNA polymerase, resulting in cell death. **Cisplatin** is a platinum-based cytotoxic agent that causes DNA crosslinking, leading to apoptosis in rapidly-dividing cancer cells. The combination is being trialed as first-line treatment for patients with CLDN18.2-positive advanced malignant solid tumors, seeking to add immunotherapy effects to established chemotherapy regimens. Preclinical and early clinical data indicate favorable tolerability and encouraging antitumor activity[1][3][5].

Other names

anti-claudin 18.2/CD3 bispecific antibody + gemcitabine + cisplatin